Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.09.19
Views: 564

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

Prof Isabelle Ray-Coquard presents data from the PAOLA-1/ENGOT-ov25 trial during a press conference at the 2019 ESMO congress.

This was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.

Watch Prof Isabelle Ray-Coquard's interview with ecancer here.

Watch Dr Susana Banerjee's comment here

Read more about the study here.

Related videos

follow us

Oncology knowledge

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation